相关实验视频

Updated: May 6, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

将液体活组织转移到肺癌治疗决策的前线

Luis E Raez¹, Carlos Carracedo², Daniel Rosas²

¹Thoracic Oncology Program, Memorial Cancer Institute, Memorial Healthcare System, Florida International University (FAU), Florida Cancer Center of Excellence, United States.

The journal of liquid biopsy

|March 3, 2025

概括

液体活检为癌症诊断和治疗监测提供了一种非侵入性方法,其疗效与非小细胞肺癌 (NSCLC) 组织分析相当. 持续的进步正在克服局限性,为更广泛的临床采用铺平道路.

科学领域:

在瘤学瘤学.
分子诊断学分子诊断
生物标志物发现发现

背景情况:

液体活检提供了瘤衍生生物标志物的非侵入性分析,包括循环瘤DNA (ctDNA) 和无细胞RNA (cfRNA).
这些方法在非小细胞肺癌 (NSCLC) 中越来越多地用于识别针对性治疗的生物标志物.
与传统的组织基因定型相比,液体活检提供了较短的治疗开始时间.

研究的目的:

探索液体活检在瘤学中的临床实用性和潜力.
为了比较液体活检与癌症诊断和治疗的传统组织分析.
突出液体活检的优点,例如更早的结果和实时监测.

主要方法:

关于NSCLC中液体活检疗效的前性多中心研究的审查.
分析循环瘤DNA (ctDNA) 和无细胞RNA (cfRNA) 以确定生物标志物.
使用下一代测序 (NGS) 进行液体活检和组织基因定型之间的周转时间和诊断准确度的比较.

主要成果:

液体活检在鉴定NSCLC患者向治疗的生物标志物方面表现出有效性.
研究表明,与分子组织检测相比,液体活检的非劣质性和等价性.
液体活检提供更短的周转时间,从而可以更早地开始治疗.

结论:

液体活检是一种有前途的非侵入性工具,可以彻底改变癌症的诊断和治疗.
克服技术限制和标准化问题将提高临床实用性.
持续的研究和验证对于将液体活检整合到标准临床实践中,以改善患者的治疗结果至关重要.

关键词:

液体活检是液体活检.下一代测序 (NGS) 是指下一代的测序.精准医学是一门精准的医学.

更多相关视频

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Published on: September 16, 2022

Author Spotlight: Expanding Interventional Pulmonology Research with Robotic-Assisted Bronchoscopy

Author Spotlight: Expanding Interventional Pulmonology Research with Robotic-Assisted Bronchoscopy

Published on: July 19, 2024

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.